TL;DR
This systematic review and network meta-analysis evaluated the diagnostic accuracy of novel urinary biomarker tests (UBTs) for non-muscle-invasive bladder cancer (NMIBC) recurrence. The findings suggest that several UBTs, particularly Uromonitor, demonstrate high diagnostic accuracy, potentially reducing the need for frequent cystoscopies and improving patient care.
What Problem Does This Paper Address?
Bladder cancer, particularly non-muscle-invasive bladder cancer (NMIBC), requires regular surveillance to detect recurrence. The current gold standard for this surveillance is cystoscopy, an invasive and uncomfortable procedure that can lead to patient anxiety and significant healthcare costs. While urine cytology is a non-invasive alternative, its diagnostic accuracy is limited, especially for low-grade tumors. Over the past decade, several novel urinary biomarker tests (UBTs) have emerged, promising improved accuracy and a less invasive approach. However, none of these UBTs are currently recommended by international guidelines, and their comparative diagnostic performance remains unclear. This paper aims to address this gap by systematically reviewing and comparing the diagnostic accuracy of these novel UBTs for NMIBC recurrence.
Methods
The authors conducted a systematic review and meta-analysis, specifically a diagnostic test accuracy (DTA) meta-analysis and a network meta-analysis (NMA).
- Systematic Review: They searched PubMed, Web of Science, and Scopus for studies published up to April 2021 that evaluated the diagnostic values of specific novel UBTs (Xpert bladder cancer, Adxbladder, Bladder EpiCheck, Uromonitor, Cxbladder Monitor, and Triage and Detect) for NMIBC diagnosis and surveillance.
- DTA Meta-analysis: For each UBT, they pooled diagnostic values (sensitivity, specificity, positive predictive value, negative predictive value) using a bivariate random-effect model. They also calculated the diagnostic odds ratio (DOR) and area under the curve (AUC) for diagnostic accuracy.
- Network Meta-analysis (NMA): This was used to compare the diagnostic values of the novel UBTs against each other and against urine cytology for NMIBC recurrence. They employed a Bayesian hierarchical model with Markov chain Monte Carlo (MCMC) simulation to estimate odds ratios (OR) and credible intervals (CrI).
- Risk of Bias Assessment: The QUADAS-2 tool was used to evaluate the quality of included studies.
Datasets
The study did not introduce new datasets. Instead, it synthesized data from 27 studies (21 for quantitative synthesis) that met their inclusion criteria. These studies involved a total of 7330 patients. The data extracted included patient demographics, tumor stage and grade, presence of CIS, previous intravesical therapy, cutoff values of biomarkers, recurrence rates, and diagnostic performance metrics (TP, TN, FP, FN, sensitivity, specificity, PPV, NPV).
Key Insights and Ideas
- UBTs Show Promise for Surveillance: The study strongly supports the utility of novel UBTs for the surveillance of NMIBC recurrence, demonstrating promising diagnostic accuracy.
- Potential to Reduce Cystoscopies: A significant insight is the potential for these UBTs to reduce the number of unnecessary cystoscopies. The analysis suggests that up to 740 cystoscopies could be avoided per 1000 patients.
- Uromonitor Leads in NMA: In the network meta-analysis, the Uromonitor test emerged with the highest diagnostic values for sensitivity, positive predictive value, and negative predictive value when compared to other UBTs and cytology.
- Cytology Still Strong for Specificity: While UBTs generally outperform cytology in sensitivity and NPV, cytology still holds an advantage in specificity, according to the NMA.
- Limited Data for Initial Diagnosis: The study highlights a significant lack of data for the use of these novel UBTs in the initial diagnosis of bladder cancer, suggesting this area requires further investigation.
- Heterogeneity is a Factor: The authors acknowledge significant heterogeneity across studies, particularly in patient populations and reference standards, which impacts the interpretation of results.
Key Results
- Overall Diagnostic Accuracy: Novel UBTs demonstrated promising pooled diagnostic values for NMIBC surveillance, with sensitivities up to 93%, specificities up to 84%, positive predictive values up to 67%, and negative predictive values up to 99%.
- Comparison with Cytology: The NMA indicated that novel UBTs generally had significantly higher diagnostic values (except for specificity) than cytology for detecting NMIBC recurrence.
- Specific UBT Performance (Recurrence):
- Xpert bladder cancer: Pooled Se: 0.72, Sp: 0.76, PPV: 0.43, NPV: 0.92. AUC: 80.7%.
- Bladder EpiCheck: Pooled Se: 0.74, Sp: 0.84, PPV: 0.48, NPV: 0.94. AUC: 86.7%.
- ADXBLADDER: Pooled Se: 0.57, Sp: 0.62, PPV: 0.29, NPV: 0.82. AUC: 59.7%.
- Uromonitor: Pooled Se: 0.93, Sp: 0.79, PPV: 0.67, NPV: 0.96. AUC: 92.4%.
- Cxbladder Monitor: Pooled Se: 0.91, Sp: 0.61, PPV: 0.16, NPV: 0.98. AUC: 91.7%.
- High-Grade Recurrence: For high-grade (HG) recurrence, pooled sensitivities were generally high (e.g., 0.88 for Xpert, 0.80 for Bladder EpiCheck), with high negative predictive values.
- Potential for Avoided Cystoscopies: Up to 740 cystoscopies could be avoided per 1000 patients in NMIBC surveillance.
Limitations and Future Work
- Heterogeneity: Significant heterogeneity was observed across studies in terms of patient populations, inclusion criteria, and diagnostic performance metrics. This limits the generalizability of the findings.
- Risk of Bias: Many studies had an unclear risk of bias, particularly regarding blinding of urologists and pathologists to UBT results.
- Limited Data for Initial Diagnosis: The study found insufficient data to reliably assess the use of UBTs for the primary diagnosis of bladder cancer.
- Lack of Blinding Data: The absence of blinding in many studies is a notable limitation.
- Limited Follow-up: Some included studies had limited follow-up periods, which could affect the assessment of long-term diagnostic accuracy.
- No Oncological Impact Data: The studies primarily focused on diagnostic performance, with a lack of data on the oncological impact (e.g., survival outcomes) of using these UBTs.
- Future Work: The authors emphasize the need for larger, head-to-head comparative studies, especially for the initial diagnosis setting. They also suggest that future research should focus on the cost-effectiveness and clinical utility of these UBTs, as well as their integration into clinical practice and guidelines. Further investigation into combinations of UBTs and cytology is also warranted.
Summary updated